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age of the patients was 63 years (range 31–79) and there 
was a male/female ratio of 18/6. The number of PS 0/1 
patients was 17/7 and locally advanced/metastatic disease 
was seen in 2/22 patients, respectively. The primary tumor 
site was the duodenum in 14 patients (58%) and jejunum 
in 10 patients (42%). The median follow-up time was 
14.7 months (3.7–40.3). The 1-year PFS was 23.3%. The 
ORR was 9/20 (45%). The median PFS and OS times were 
5.9 months (95% confidence interval [CI] 3.0–10.2) and 
17.3 months (95% CI 11.7–19.0), respectively. Major grade 
3/4 toxicities were neutropenia (38%), anemia/peripheral 
neuropathy (25%), and stenosis (17%). There were no 
treatment-related deaths.
Conclusions Although the primary endpoint was not met, 
mFOLFOX6 showed effective and good tolerance as a first-
line treatment for SBA.
Abstract 
Background Several studies have suggested that chemo-
therapy prolonged survival in patients with metastatic or 
recurrent small bowel adenocarcinoma (SBA); however, 
there is still no standard chemotherapy regimen. Here, 
we evaluated the efficacy and safety of a 5-fluorouracil 
(5-FU)/L-leucovorin (l-LV)/oxaliplatin (mFOLFOX6) pro-
tocol as a first-line therapy for patients with SBA.
Patients and methods This was a multicenter, single-arm, 
open-label phase II study. Eligibility criteria included histo-
logically confirmed adenocarcinoma, age 20–80 years, and 
an Eastern Cooperative Oncology Group performance sta-
tus (PS) of 0–2. The primary endpoint was 1-year progres-
sion-free survival (PFS). The secondary endpoints included 
overall response rate (ORR), overall survival (OS), overall 
PFS, and safety.
Results Between April 2010 and November 2012, 24 
patients were enrolled from 12 institutions. The median 
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Introduction
Adenocarcinoma of the small bowel (SBA) is a rare form 
of gastrointestinal cancer. SBA accounts for approximately 
one-third of all small intestinal malignancies, with the 
other major tumor types being neuroendocrine carcinomas, 
sarcomas, and lymphomas [1, 2]. The age-standardized 
incidence rates of SBA were reported to be 8.1 per mil-
lion men and 5.5 per million women in the USA in 1995–
2008 [3]. In Sweden, the age-standardized incidence of all 
malignant small bowel tumors (including adenocarcino-
mas, carcinoids, sarcomas, and lymphomas) increased from 
14.2−19.7 per million people. In particular, the incidence 
of duodenal adenocarcinoma increased dramatically from 
0.7−4.2 per million people during the period 1960–2009 
[4].
As symptoms of SBA are usually nonspecific, diagnosis 
is difficult. Most affected patients present with advanced-
stage disease and either lymph node involvement or distant 
metastatic disease [5]. Surgical management, with regional 
lymph node dissection is the only therapeutic modality 
with curative potential for localized SBA. For unresectable 
or recurrent tumors, chemotherapy regimens are gener-
ally used, as indicated for other gastrointestinal malignan-
cies. Although several retrospective studies suggested that 
chemotherapy prolonged the survival of patients with unre-
sectable or recurrent SBA [6–10], there are still no standard 
treatment protocols, and no randomized controlled trials 
have been carried out for these types of tumor [6–17].
Fluorouracil (5-FU) is the most commonly used agent 
for the treatment of unresectable or recurrent SBA, and 
various 5-FU-based regimens have been used [8–20]. In a 
retrospective analysis, Overman et al. reported that combi-
nation therapy with 5-FU and platinum compounds showed 
better results than other regimens [18]. Among the various 
types of combinations of 5-FU and platinum, oxaliplatin-
containing regimens showed better efficacy in several stud-
ies. To date, two multicenter retrospective studies have 
been conducted. Zaanan et al. and Tsushima et al. reported 
median progression-free survival (PFS) times of 6.9 and 
9.3 months, respectively, and median overall survival (OS) 
times of 17.8 and 22.2 months, respectively, with leucov-
orin + 5-FU + oxaliplatin (FOLFOX) therapy [19, 20]. In 
addition, two prospective studies have been reported. Over-
man et al. and Xiang et al. reported on CAPOX (capecit-
abine + oxaliplatin) therapy and FOLFOX4 therapy 
and found median times to treatment failure of 11.3 and 
7.8 months, respectively, and median OS times of 20.4 
and 15.2 months, respectively [21, 22]. Although combina-
tion therapy with 5-FU and oxaliplatin appears promising, 
to date the efficacy and safety of the mFOLFOX6 regi-
men (defined below) for SBA have not been demonstrated 
in any study. Therefore, we investigated the efficacy and 
safety of this regimen for Japanese patients with unresect-
able or recurrent SBA.
Patients and methods
Patients
All eligible patients were required to have histologi-
cally confirmed unresectable or recurrent SBA, exclud-
ing any ampullary carcinomas. Inclusion criteria were 
age 20–80 years; Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) of 0–2; and adequate 
hematologic parameters (white blood cell count ≥3000 
and ≤12,000/mm3, neutrophil count ≥1500 cells/mm3, 
platelet count ≥100,000 cells/mm3, and hemoglobin ≥8 g/
dL), normal hepatic function (total bilirubin ≤2.0 g/dL, 
and transaminases ≤100 IU/L), and normal renal function 
(creatinine ≤1.5 mg/dL). Prior chemotherapy or radio-
therapy was not allowed, but prior use of adjuvant chemo-
therapy at least 6 months before evidence of recurrence was 
permitted.
Patients with peripheral neuropathy of grade ≥1, brain 
metastases, concurrent therapeutic warfarin use, uncon-
trolled concurrent serious medical illnesses, pregnant or 
breast-feeding women, or patients with gastrointestinal 
malabsorption were not eligible to participate in the study.
Written informed consent was obtained from all patients, 
and the institutional review board of each participating hos-
pital approved the study. This study was registered in the 
University Hospital Medical Network Clinical Trials Reg-
istry in Japan (UMIN000002797; http://www.umin.ac.jp/
ctr/).
Study design
This was an open-label, single-arm, multicenter, phase II 
study conducted at 24 academic centers in Japan. Treat-
ment consisted of intravenous oxaliplatin (85 mg/m2) and 
l-leucovorin (l-LV; 200 mg/m2) administered intravenously 
over a 2-h period on day 1, followed by a bolus of 5-FU 
(400 mg/m2) and a 46-h infusion of 5-FU (2400 mg/m2), 
defined as the mFOLFOX6 regimen. Treatment cycles were 
repeated every 14 days.
Staging procedures were conducted every 8 weeks. 
Patients were removed from the study if they withdrew 
their consent, if they experienced unacceptable toxicity, if 
they had a treatment delay of >2 weeks because of toxicity 
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from the treatment, or if the investigator deemed that with-
drawal was in the patient’s best interest.
Dose reductions
All toxicities were graded according to the National Can-
cer Institute Common Toxicity Criteria, version 3.0 (http://
ctep.cancer.gov/protocolDevelopment/electronic_applica-
tions/ctc.htm), except for neurotoxicity. Initiation of a cycle 
of mFOLFOX6 required grade ≤1 granulocytopenia, grade 
≤1 thrombocytopenia, and recovery from any treatment-
related nonhematologic toxicity (excluding alopecia and 
neurosensory toxicity) to baseline or to grade ≤1.
Treatments with 5-FU and oxaliplatin were interrupted 
during a cycle if there was grade 3 or 4 hematologic toxic-
ity (excluding anemia), or grade ≥2 nonhematologic toxic-
ity (excluding nausea, vomiting, fatigue, or anorexia). The 
5-FU dosage was reduced by 17% for grade 2 hand–foot 
syndrome, by 50% for grade 3 hand–foot syndrome, by 
25% for grade 3 nonhematologic toxicity, by 50% for grade 
4 nonhematologic toxicity, or by 25% for a delay in hema-
tologic recovery of >1 week (excluding anemia). The 5-FU 
and oxaliplatin dosages were reduced, respectively, by 20 
and 25% for grade 3 or 4 hematologic toxicity (excluding 
anemia), grade 3 or 4 nonhematologic toxicity (excluding 
nausea, vomiting, fatigue, or anorexia), or a delay in hema-
tologic recovery of >1 week (excluding anemia). The oxali-
platin dosage was reduced by 25% for paresthesia with pain 
or functional impairment >7 days, and was discontinued if 
paresthesia with pain or functional impairment persisted 
throughout any treatment cycle.
Statistical analysis
All analysis followed the intent-to-treat principle. The pri-
mary endpoint was 1-year PFS as assessed by the treat-
ing investigator. Responses were determined according to 
Response Evaluation Criteria In Solid Tumors (RECIST) 
(version 1.1) (http://www.irrecist.com). Secondary end-
points included overall response rate (ORR), OS, PFS, and 
safety. PFS and OS were defined as the time from the date 
of registration to the date of disease progression or death, 
respectively. PFS and OS were analyzed using the Kaplan–
Meier method. The log-rank test was used to compare 
survival rates between groups. Multivariate analyses were 
performed using the Cox proportional hazards test. Toxic-
ity data were analyzed in all patients who received at least 
one dose of study medication. Statistical analysis was per-
formed by a statistician (KY) at an independent academic 
research organization. All statistical analysis was per-
formed using SAS Release 9.13 (SAS Institute Inc., Cary, 
NC, USA). Initially, a total of 31 patients was determined 
to reject the 1-year PFS of 25% under the expectation of 
45% with a power of 0.80 and a one-sided alpha of 0.10. 
However, on 23 October 2012, because of the slow accrual 
of patients, the sample size was amended to 24 patients 
for final analysis to provide a one-sided 90% confidence 
interval (CI) for the 1-year PFS rate, which would exclude 
a threshold value of 25% if the observed 1-year PFS was 
~45%. Following the protocol amendment to sample size, 
the primary analysis was an evaluation of 1-year PFS using 
the Kaplan−Meier method relative to the pre-specified 
threshold values of 25%.
Immunohistochemical analysis
Immunohistochemical (IHC) staining was performed 
on 5-μm-thick unstained sections from tissue microar-
ray blocks using antibodies to cytokeratin 7 (CK7) (clone 
OV-TL12/30; Dako, Carpinteria, CA, USA; 1:300 dilu-
tion), to cytokeratin 20 (CK20) (clone Ks20.8; Dako; 
1:200 dilution), to homeobox protein CDX2 (clone CDX2-
88; Abcam, Cambridge, MA, USA; 1:100 dilution), and 
to epidermal growth factor receptor(EGFR) (clone 3C6; 
Roche Diagnostics, Mannheim, Germany; 1:100 dilution). 
IHC staining of human epidermal growth factor receptor 2 
(HER2) was performed using the Ventana Ultra View DAB 
detection kit (Ventana Medical Systems, Tucson, AZ, USA) 
and the Ventana PATHWAY HER2/neu rabbit monoclo-
nal antibody (4B5) on a Ventana BenchMark XT immu-
nostainer (Ventana Medical Systems). All slides from each 
tumor were evaluated by a single pathologist independently 
based on the following criteria. Expression of CK7, CK20, 
and CDX2 was considered positive if 10% of the tumor 
cells showed immunoreactivity. For EGFR, both the per-
centage of positive tumor cells and the intensity of positive 
staining were graded according to a previous report [23]. 
Total grades were generated on a scale of 0–6 and consid-
ered positive if the score was 2–6. The staining for HER2 
was graded according to the guidelines for such testing in 
gastric cancers [24].
Results
Baseline characteristics
Between April 2010 and November 2012, 24 patients with 
advanced SBA were enrolled from 12 institutions in Japan. 
The baseline characteristics of the intention-to-treat popula-
tion are listed in Table 1. Metastatic disease was present in 
22 of the patients, and the ECOG performance status was 0 
or 1 in all patients. There were 14 patients with SBA in the 
duodenum (58%) and 10 patients with SBA in the jejunum 
(42%). The liver was the most common site of metastasis 
in 10 patients (40%). Three patients showed recurrence 
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after curative resection of the SBA without receiving adju-
vant therapy. Seven patients including the above recurrence 
cases underwent primary resection, and six underwent 
bypass therapy to resolve stenosis of the primary tumor. 
Eleven patients (46%) had not undergone any prior surgery. 
Four patients were excluded from the analysis of response 
rate (RR) because of lack of target lesion of RECST ver 
1.1. The median follow-up time was 14.7 months (range 
3.7–40.3).
Chemotherapy and response
The ORR was 9/20 (45%) and the disease control rate was 
16/20 (80%). One patient with liver metastasis had a com-
plete response (CR) to mFOLFOX6. This patient started 
study treatment after undergoing resection of the SBA 
(pancreaticoduodenectomy), and we determined a CR after 
20 cycles of chemotherapy. This patient was currently alive 
without evidence of disease at 12 months after the initiation 
of treatment. Second-line chemotherapy was received by 
12 patients, while six patients received additional mFOL-
FOX6 therapy.
Efficacy
The primary endpoint for this study was 1-year PFS as 
assessed by the treating investigator. With a median fol-
low-up of 14.7 months, the PFS rate at 1 year was 23% 
(95% CI 8.6–44.2%). The median PFS and OS were 
5.4 months (95% CI 4.8–6.0 Fig. 1), and 17.3 months 
(95% CI 11.7–19.0 Fig. 2), respectively. An exploratory 
analysis was conducted to determine the prognosis fac-
tors that might have influenced OS (Table 2). Parameters 
studied included age, PS, primary site and histologi-
cal grade of the tumor, resection of the primary tumor 
or bypass, numbers of metastatic organs, and serum 
Table 1  Clinical and 
pathological characteristics of 
the patients
ECOG Eastern Cooperative Oncology Group, CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic 
antigen, PS performance status
N = 24 (%)
Gender: male/female 18/6 75/25
Age: median, years (range) 63 (31–79)
ECOG PS: 0/1/2 17/7/0 71/29/0
Disease status: locally advanced/metastatic 2/22 8/92
Metastatic site: liver/lung/peritoneum/distant lymph node/other 10/3/2/9/4 42/13/8/39/17
Primary tumor site: duodenum/jejunum/ileum 14/10/0 58/42/0
Histology: well to moderate/poor/muc/sig 17/4/2/1 71/17/8/4
CEA <5/5 15/9 63/38
CA19-9 <37/37 10/14 42/58
Prior surgery: primary resection/bypass/none 7/6/11 29/25/46
Prior adjuvant chemotherapy: none/yes 3/0
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Fig. 1  The survival rate in this study: progression-free survival (PFS) 
curve
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Fig. 2  The survival rate in this study: overall survival (OS) curve
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carcinoembryonic antigen (CEA) and carbohydrate anti-
gen (CA)19-9 levels. Upon univariate analysis, good PS 
(0), location in the jejunum, resection of the primary 
tumor or bypass, and a low level of serum CEA (<5 ng/
mL) were all significantly associated with longer OS. 
However, upon multivariate analysis, only resection of 
primary tumor or bypass was an independent predictor 
of better OS (P = 0.023). The RR was slightly higher in 
patients with a tumor in the jejunum (4/7; 57%) than in 
the duodenum (5/13; 38%).  
An exploratory analysis was conducted to determine 
the characteristic factors of the patients that might have 
influenced response. However, no difference between the 
responder and non-responder patients was identified for 
age, gender, PS, histological grade, tumor resection or 
bypass, location of primary tumor and metastasis, serum 
CEA and CA19-9 levels.
Toxicity
All 24 patients who received one dose of the study treat-
ment were evaluated for toxicity. The common treatment-
related grade 3–4 adverse events are listed in Table 3. The 
most common events were neutropenia (38%), anemia/
peripheral neuropathy (25%), stenosis (17%), fatigue/
anorexia/bilirubin increase (8%), and diarrhea (4%). One 
nonhematological grade 4 toxicity occurred; this patient 
had symptomatic cerebrovascular ischemia and was 
under treatment for type 2 diabetes and hypertension, and 
discontinued chemotherapy. There were no treatment-
related deaths.
Immunohistochemistry
We were able to collect 13 tumor samples from the primary 
site and performed IHC analysis.
The most commonly expressed immunophenotypic 
marker was CDX2, observed in seven patients (54%). 
Expression of CK20 occurred in 5 (38%) patients, and 
expression of CK7 occurred in 4 (31%) patients. The tis-
sues demonstrated great variability for CK7, CK20, and 
CDX2. There was no significant difference in the expres-
sion of CK7, CK20, and CDX2 between the duodenal and 
nonduodenal SBA. Expression of EGFR score 2–6 was 
observed in 3 (23%) patients. Expression of HER2 was not 
observed in this analysis.
There was no significant association between immu-
nophenotypes and patient survival.
Discussion
In the treatment of patients with advanced SBA, no prospec-
tive studies evaluated the benefit of chemotherapy compared 
with best supportive care. Single-institution retrospective 
studies have suggested that palliative chemotherapy confers 
a survival benefit to such patients [6, 8, 9]. In the largest ret-
rospective analysis that evaluated 113 patients with advanced 
SBA, palliative chemotherapy predicted OS in a multivariate 
analysis (hazard ratio [HR] 0.47) [8]. Therefore, although no 
Table 2  Univariate and multivariate analysis of factors associated 
with survival
CEA carcinoembryonic antigen, CI confidence interval, ECOG East-
ern Cooperative Oncology Group, HR hazard ratio, PS performance 
status
Univariate Multivariate
N HR (95% CI) P HR (95% CI) P
ECOG PS
 0 17
 1 7 3.69 (1.31–
10.38)
0.014 2.60 (0.73–9.28) 0.14
Primary site
 Jejunum 10
 Duode-
num
14 2.88 (0.89–9.27) 0.077 2.85 (0.85–9.52) 0.090
Prior surgery
 Yes 13
 No 11 2.83 (1.02–7.84) 0.046 3.98 (1.21–
13.07)
0.023
Serum CEA (ng/mL)
 <5 15
 ≥5 9 2.51 (0.90–7.01) 0.079 1.61 (0.43–6.00) 0.48
Table 3  The most common treatment-related toxicities based on the 
Common Terminology Criteria for Adverse Events (CTCAE; Ver. 3.0)
Any grade N (%) Grade 3/4 N (%)
Neutropenia 12 (50) 9 (38)
Anemia 13 (54) 6 (25)
Thrombocytopenia 10 (42) 0 (0)
Fatigue 18 (75) 2 (8)
Nausea 18 (75) 0 (0)
Vomiting 9 (38) 0 (0)
Diarrhea 11 (46) 1 (4)
Stomatitis 5 (21) 0 (0)
Bilirubin elevation 4 (17) 2 (8)
Peripheral neuropathy 19 (79) 6 (25)
Hand–foot syndrome 4 (17) 0 (0)
Pneumonitis 2 (8) 0 (0)
Stenosis 9 (38) 4 (17)
Hemorrhage 1 (4) 1 (4)
Cerebrovascular 
ischemia
1 (4) 1 (4)
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prospective study has evaluated outcomes, palliative chemo-
therapy is considered a standard treatment for patients with 
unresectable or recurrent SBA. In the past decades, these 
patients had been treated with the same chemotherapy regi-
men used for colorectal cancer (CRC) or gastric cancer. 
Therefore, in retrospective studies on patients with SBA, the 
most common regimen was 5-FU or 5-FU with a platinum 
agent (Table 4). Among them, combination chemotherapy 
of 5-FU with platinum compounds including oxaliplatin 
seemed to be more effective than other regimens.
Our study demonstrated an RR of 45%, a median 
PFS of 5.4 months, and a median OS of 17.3 months in 
patients given the mFOLFOX6 regimen. To our knowl-
edge, only two prospective phase II studies have used the 
combination of fluoropyrimidine and oxaliplatin. Over-
man et al. reported on a capecitabine and oxaliplatin 
(CAPOX) regimen [21] and Xiang et al. reported on a 
mFOLFOX6 regimen but omitted a bolus 5-FU treatment 
[22]. The RR and median OS were similar in these stud-
ies. However, the PFS of our study was worse than that 
of the CAPOX regimen. Ono possibility is that patients 
with duodenal cancer were more frequently seen in our 
study than in the CAPOX study (58 vs 23%). Although 
there was no statistical difference in multivariate analy-
sis for OS, the RR for patients with a tumor in the duo-
denum appeared lower than in the jejunum (38 vs 57%, 
respectively), and location in the jejunum was signifi-
cantly associated with a longer OS in univariate analysis 
(P = 0.077). The primary site was demonstrated as a pre-
dictive or as a worse factor for OS in previous analyses 
and our study, respectively [25, 26]. This difference 
might reflect the heterogeneous nature of the epithelium 
of tumor origin between the duodenum and jejunum.
This study did not meet the primary endpoint because 
of the small sample size. However, the differences in PFS 
between the two prospective studies (above) and our result 
are small. Therefore, the survival benefit of combining fluo-
ropyrimidine and oxaliplatin combination was confirmed as 
a first-line chemotherapy regimen for patients with unre-
sectable or recurrent SBA.
In multivariate analysis, only resection of the primary 
tumor or bypass was an independent predictor of better OS 
(P = 0.023). Severe stenosis of grade ≥3 which requests 
resection of the primary tumor or bypass occurred in 4 
patients (17%, 4/23) in this study. Resection of the primary 
tumor was also demonstrated to be a factor predictive of a 
better OS in other reports [18]. Palliative tumor resection 
has been traditionally advocated in metastatic CRC to pre-
vent symptoms and complications linked to the primary 
tumor, such as obstruction, perforation, or bleeding. The risk 
of obstruction caused by the tumor during initial chemother-
apy was 6–29% in patients with CRC [27, 28]. In this study, 
severe stenosis (grade ≥3) occurred in 3 patients (27%, 
3/11) among the patients without resection of the primary 
tumor or bypass. All cases occurred within 2 months after 
starting chemotherapy. If the lumen of the small intestine is 
narrower than the colorectum, then we should consider that 
stenosis is likely to occur at an early stage of chemotherapy.
There were some limitations to our study. First, the 
small sample size hampered comparisons between 
Table 4   Summary of previous studies on patients with SBA
5-FU fluorouracil, ECF epirubicin, cisplatin and 5-FU, FAM 5-FU adriamycin and mitomycin, FOLFOX oxaliplatin, leucovorin and 5-FU, 
CAPOX capecitabine and oxaliplatin, RR response rate, PFS progression-free survival, TTP time to progression, MST median survival time
Authors Study Type Pts No. Regimen RR (%) PFS/TTP (M) MST (M)
Xiang et al. [22] P II 33 FOLFOX 48.5 7.8 15.2
Tsushima et al. [20] Retro 22 FOLFOX 42 9.6 22.2
Zaanan et al. [19] Retro 38 FOLFOX 34 6.9 17.8
Overman et al. [21] P II 30 CAPOX 50 11.3 20.4
Suenaga et al. [15] Retro 10 5-FU-based 10 2.9 12
Overman et al. [18] Retro 29 5-FU and Platinum 46 8.7 14.8
Aparicio et al. [32] Retro 21 FOLFOX NR 7 NR
Czaykowski et al. [9] Retro 37 5-FU-based 5 NR 15.6
Fishman et al. [8] Retro 44 Various 29 NR 18.6
Gibson et al. [11] P II 39 FAM 18 5.0 8
Locher et al. [13] Retro 20 5-FU and Platinum 21 8.0 14
Dabaja et al. [6] Retro 48 NR NR NR 11
Crawley et al. [14] Retro 8 ECF or 5-FU 38 7.8 13
Jigyasu et al. [16] Retro 14 5-FU-based 7 NR 9
Morgan and Busuttil [33] Retro 7 5-FU-based 0 NR NR
Rochlin et al. [34] Retro 11 5-FU 36 3.8 NR
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subgroups. Nevertheless, to separate the heterogene-
ity in the survival outcomes associated with the primary 
site (duodenum vs jejunum) and prior surgery (resection 
of the primary tumor or bypass vs without resection), an 
exploratory analysis of the subgroups were performed. 
Second, IHC analysis used only a small subsample of the 
patients. No information was obtained from this analysis. 
Consequently, firm conclusions cannot be drawn from the 
subgroup and IHC analyses because the rarity of this dis-
ease hampers large-scale studies.
Importantly, this trial demonstrates the feasibility of 
the completion of phase II studies in such rare tumor 
types, and should promote more robust research on these 
orphan tumors. In addition, given the overall tolerability 
of the regimen, it is logical to investigate the role of tar-
geted therapies in combination with mFOLFOX6.
The main challenge for the future will be to identify a 
molecular marker involved in small-bowel carcinogenesis 
that can predict chemosensitivity, and thus improve patient 
survival. In patients with unresectable CRC, the addition of 
bevacizumab to mFOLFOX6 was found to prolong PFS com-
pared with mFOLFOX6 alone, and clinical trials that investi-
gate mFOLFOX6 in combination with agents targeting angi-
ogenesis would be reasonable for patients with SBA [29]. In 
addition, activation of mutations in the KRAS (or RAS) onco-
gene occur at a similar frequency in both SBA and colorectal 
adenoma tumors, which suggests a potential role for EGFR 
inhibition in a subset of patients with SBA [30, 31].
The infrequency of SBA made it difficult to conduct 
a prospective study. It is extremely unlikely that a rand-
omized trial comparing two chemotherapy regimens could 
be undertaken. However, we have conducted this prospec-
tive phase II trial within a new cooperative group in Japan. 
It provides important insights for the treatment of patients 
with SBA. The mFOLFOX6 regimen proved effective and 
probably represents a new standard treatment for patients 
with an unresectable or recurrent SBA. In the future, the 
mFOLFOX6 regimen in combination with molecular target-
ing therapy should be evaluated prospectively to improve 
the outcomes even for patients with SBA; however, world-
wide multi-institutional cooperation will be necessary for 
investigating such a rare disease.
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